**Product Name**: BRD6989  
**Catalog Number**: T14778  
**CAS Number**: 642008-81-9  
**Molecular Formula**: C16H16N4  
**Molecular Weight**: 264.33

**Description**: BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes. It selectively binds a complex of CDK8 (IC50: ~200 nM).

**Storage**: 2 years -80°C in solvent; 3 years -20°C powder;

<table>
<thead>
<tr>
<th>Receptor (IC50)</th>
<th>CDK8</th>
<th>~200 nM</th>
</tr>
</thead>
<tbody>
<tr>
<td>recombinant CDK8</td>
<td>~0.5 μM</td>
<td></td>
</tr>
<tr>
<td>recombinant CDK19</td>
<td>&gt;30 μM</td>
<td></td>
</tr>
<tr>
<td>IL-10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**In vitro Activity**

Pretreatment of BMDCs with BRD6989 (0-100 μM; for 48 hours) increases IL-10 production (EC50: ~1 μM). BRD6989 (0.6, 1.7, 5, 15 μM) suppresses phosphorylation of the STAT1 transactivation domain at Ser727 in IFNγ-stimulated BMDCs. BRD6989 (5 μM; 24 hours) enhances IL-10 production in activated human and murine macrophages and dendritic cells. BRD6989 (5 μM; ~2 hours) suppresses induction of STAT1–STAT2 activity and NF-κB activation to a varying degree after stimulation of BMDMs.

**Reference**


**FOR RESEARCH PURPOSES ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.**

Information for product storage and handling is indicated on the product datasheet. Targetmol products are stable for long term under the recommended storage conditions. Our products may be shipped under different conditions as many of them are stable in the short-term at higher or even room temperatures. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, please follow the storage recommendations on the product data sheet.